Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capsaicin
Drug ID BADD_D00353
Description Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
Indications and Usage The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.
Marketing Status approved
ATC Code M02AB01; N01BX04
DrugBank ID DB06774
KEGG ID D00250
MeSH ID D002211
PubChem ID 1548943
TTD Drug ID D0U5CE
NDC Product Code 73102-046; 83158-387; 24286-1559; 45865-773; 49671-001; 49671-002; 59779-381; 68016-067; 69420-6025; 70656-742; 71480-831; 72490-018; 72490-023; 72490-026; 72512-929; 79643-002; 66499-0036; 11822-7448; 50268-195; 50488-1075; 50488-2025; 59088-310; 0363-9902; 69420-7025; 0536-2525; 72490-024; 72512-928; 75249-006; 51686-0002; 41167-7514; 49873-608; 51672-5308; 59316-996; 63187-660; 69842-313; 0536-1118; 70583-733; 71178-777; 72490-032; 72490-037; 53943-904; 59088-479; 72490-014; 72490-028; 72490-029; 72490-033; 72490-034; 72512-930; 81877-515; 50268-198; 52099-8005; 61787-443; 62742-4216; 63868-308; 71073-208; 71178-776; 73102-117; 73141-559; 73287-018; 75249-003; 17353-0010; 10742-8127; 11993-001; 35192-040; 59088-433; 59779-770; 65923-123; 72490-010; 72490-022; 72490-035; 72490-039; 72683-003; 72683-006; 73486-100; 49452-1321; 51686-0003; 62991-3129; 11993-000; 35192-023; 41250-842; 46122-753; 46581-700; 50268-197; 55264-110; 70000-0556; 71659-842; 72490-036; 73454-001; 82345-855; 59568-9200; 50488-1025; 61787-556; 70656-741; 72490-025; 72490-027; 72490-030; 73557-180; 82777-001; 51824-094; 55614-410; 0363-0837; 67510-0303; 68071-3430; 0536-1264; 71101-904; 72490-019; 81533-200; 51927-1807; 81961-001; 49035-890; 50488-1060; 69396-103; 70000-0549; 72490-012; 72490-013; 72490-021; 72847-316; 82531-001; 51552-0129; 11822-4210; 42903-008; 50268-196; 52000-040
UNII S07O44R1ZM
Synonyms Capsaicin | Capsaicine | 8-Methyl-N-Vanillyl-6-Nonenamide | 8 Methyl N Vanillyl 6 Nonenamide | Antiphlogistine Rub A-535 Capsaicin | Axsain | Zacin | Capsidol | Zostrix | Capzasin | Gelcen | Katrum | NGX-4010 | NGX 4010 | NGX4010 | Capsicum Farmaya | Capsin
Chemical Information
Molecular Formula C18H27NO3
CAS Registry Number 404-86-4
SMILES CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site anaesthesia17.02.06.010; 12.07.01.017; 08.02.01.017--Not Available
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.005--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site oedema08.02.01.020; 12.07.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash12.07.01.016; 08.02.01.016; 23.03.13.008--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Application site warmth12.07.01.029; 08.02.01.029--Not Available
Blood pressure increased13.14.03.005--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Burns second degree23.03.11.028; 12.05.04.003--Not Available
Cough22.02.03.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dysgeusia17.02.07.003; 07.14.03.001--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Herpes zoster23.11.05.005; 17.09.03.026; 11.05.02.003--
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Infection11.01.08.002--Not Available
Instillation site pain08.02.01.008; 12.07.01.008--Not Available
Muscle spasms15.05.03.004--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene